As this was not the case for our patient cohort, the CD8+ T cell phenotypes we observed could be more specific to advanced BrMs in which tumor-infiltrating lymphocytes may be resident in the TME for months before diagnosis and treatment. Here, CD8A is linked to neoplasm.